Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results.
about
Update on the management of Philadelphia chromosome positive chronic myelogenous leukemia: role of nilotinibRapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy.Nilotinib in patients with systemic mastocytosis: analysis of the phase 2, open-label, single-arm nilotinib registration studyNilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study.Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era.European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors.Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase.Treatment-, patient-, and disease-related factors and the emergence of adverse events with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.A critical review of trials of first-line BCR-ABL inhibitor treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phase.Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management.Update on emerging treatments for chronic myeloid leukemia.Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily.Management of advanced-phase chronic myeloid leukemia.Accelerated Phase CML: Outcomes in Newly Diagnosed vs. Progression From Chronic Phase.Management of Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia in the Accelerated or Blastic Phase.Second line small molecule therapy options for treating chronic myeloid leukemia.Advanced phase chronic myeloid leukaemia (CML) in the tyrosine kinase inhibitor era - a report from the Swedish CML register.Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring.Effect of the tyrosine kinase inhibitor nilotinib in patients with hypereosinophilic syndrome/chronic eosinophilic leukemia: analysis of the phase 2, open-label, single-arm A2101 study.Superiority of allogeneic hematopoietic stem cell transplantation to nilotinib and dasatinib for adult patients with chronic myelogenous leukemia in the accelerated phase.Omacetaxine mepesuccinate in patients with advanced chronic myeloid leukemia with resistance or intolerance to tyrosine kinase inhibitors.Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients.Phase II trial of homoharringtonine with imatinib in chronic, accelerated, and blast phase chronic myeloid leukemia.Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial.[Chronic myelogenous leukemia].Patients with Philadelphia-positive leukemia with Y253H or F359V mutation have a high risk of developing new mutations in the setting of dasatinib resistance.[Tailored management of chronic myeloid leukemia].Chronische myeloische LeukämieNilotinib population pharmacokinetics and exposure-response analysis in patients with imatinib-resistant or -intolerant chronic myeloid leukemia
P2860
Q26751285-9459835C-C6FA-4FC1-AC18-00753DE56202Q33404602-46DF127E-3FD2-48E4-8FCB-B6A00907F7E7Q33423072-CCD38CCB-DF2D-44B5-97C0-59351BC37694Q34639998-A48277FF-EABF-4122-BF4D-9DB1F5479B7BQ35953410-915C2EE4-F9FB-44BE-AE73-54080CC304B0Q37026032-BB8693B9-C326-4188-85AD-41D5B08BFB3DQ37461942-A165FBB0-5398-41CD-B4C1-34E6F138B06BQ37647076-E6BB5D65-8BD5-49F4-B71C-8E3D4066DEE9Q38095848-EF6C2CBA-FAB8-475F-B596-A72015866E67Q38149613-BBF64BF2-F141-4064-B989-E62081C15A30Q38204330-E3E19088-645A-4CB0-83E9-01C4AE474A72Q38397515-A10E9BAD-A70B-4526-A94A-7083007A712DQ38436037-8521F39B-E293-4AED-816B-FF31E4DE8A2CQ38452040-A03031D5-0A44-4BDF-8F3A-23FA09207C6EQ38757051-997DE67D-FF0C-4D07-9821-63D3FE90C989Q38767908-CE391988-146B-4817-8AC7-12C50571D544Q38789049-62833411-6B6B-4151-8003-9958E22A11BBQ39591396-B9AC6DC1-D456-43BE-876A-791B219E5100Q40957470-F611BE1D-DB84-454D-BF40-76E825B657FDQ41402735-703B52B4-D5D5-4585-AACD-E777D8E4448AQ41649368-949F0AC6-5604-4519-A82F-ECA42120F463Q43719917-2AF4495A-C52D-4984-B518-49EACEE2B7BFQ45340032-2F94DE25-14B2-4EB6-8CCB-75264A61903EQ46976339-22E9717F-E285-4831-8390-3D5A5879975CQ52641875-0A3EC8E9-14DB-4FA2-B52D-2BAE46BCCDC0Q54167458-CC14BDAD-AB67-4342-B964-F53434AAFAE8Q54310937-267B3CA2-478A-4706-A7DE-7ED735527B23Q54398375-27C2379A-019D-4044-965C-A7C27AC59CF0Q58023770-F461ADC8-A948-4E92-9E8F-8F23218A5D1DQ58414318-5B56B9E3-9F4E-46AC-B2DC-77D130EFCA2E
P2860
Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results.
description
2011 nî lūn-bûn
@nan
2011 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Nilotinib in patients with Ph+ ...... e: 24-month follow-up results.
@ast
Nilotinib in patients with Ph+ ...... e: 24-month follow-up results.
@en
type
label
Nilotinib in patients with Ph+ ...... e: 24-month follow-up results.
@ast
Nilotinib in patients with Ph+ ...... e: 24-month follow-up results.
@en
prefLabel
Nilotinib in patients with Ph+ ...... e: 24-month follow-up results.
@ast
Nilotinib in patients with Ph+ ...... e: 24-month follow-up results.
@en
P2093
P2860
P356
P1433
P1476
Nilotinib in patients with Ph+ ...... e: 24-month follow-up results.
@en
P2093
G J Ossenkoppele
H M Kantarjian
J F Apperley
M Baccarani
N J Gallagher
P D le Coutre
R Blakesley
P2860
P2888
P304
P356
10.1038/LEU.2011.323
P577
2011-11-11T00:00:00Z
P6179
1050607241